Log In Sign up
The largest database of trusted experimental protocols

Recombinant murine il 2

Manufactured by Miltenyi Biotec
Visit Supplier
Sourced in Germany

Recombinant murine IL-2 is a protein produced using recombinant DNA technology that is derived from the interleukin-2 (IL-2) cytokine found in mice. It is used as a research tool in various scientific applications.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd3 28 stimulation beads, by Miltenyi Biotec (2 mentions) Recombinant murine pd l1 protein, by R&D Systems (2 mentions) Human il 2, by Miltenyi Biotec (1 mentions) Murine il 6, by Miltenyi Biotec (1 mentions) Recombinant human il 1β, by R&D Systems (1 mentions) Il 23, by R&D Systems (1 mentions) Tgf β, by R&D Systems (1 mentions) Mouse il 12 p70 quantikine elisa kit, by R&D Systems (1 mentions) Celltiter glo luminescence kit, by Promega (1 mentions)

Spelling variants of this product

Recombinant IL-2 (10 citations)

4 protocols using recombinant murine il 2

1

Antibody, Cytokine, and Chemical Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies are listed in Supplemental Table 2. Recombinant murine IL-2, human IL-2, and murine IL-6 were purchased from Miltenyi Biotec. Recombinant human IL-1β, IL-23, and TGF-β were purchased from R&D Systems. NECA and CSC were purchased from Merck.
Suga K., Suto A., Tanaka S., Sugawara Y., Kageyama T., Ishikawa J., Sanayama Y., Ikeda K., Furuta S., Kagami S.I., Iwata A., Hirose K., Suzuki K., Ohara O, & Nakajima H. (2023). TAp63, a methotrexate target in CD4+ T cells, suppresses Foxp3 expression and exacerbates autoimmune arthritis. JCI Insight, 8(10), e164778.
+ Open protocol
+ Expand
2

OT1 CD8+ T-cell Activation and Expansion

Check if the same lab product or an alternative is used in the 5 most similar protocols
OT1 CD8+ T-cells were activated and expanded using the H-2Kb-restricted OVA MHC class I epitope (OVA257–264; SIINFEKL), according to previously published methods.[19 (link)] Antigen-experienced T-cells were viably frozen and subsequently thawed for experiments, allowing cells to recover overnight. Cells were incubated for 6 d with 100 IU mL−1 recombinant murine IL-2, anti-CD3/28 stimulation beads according to manufacturer protocol (Miltenyi, 130-095-925), and 1 µg mL−1 recombinant murine PD-L1 protein (R&D systems, 1019-B7), with media and reagents changed out every 48 h. On day 7, T-cells were coincubated with B16-OVA tumor cells at a 10:1 effector to target ratio in 100 µL media for 3–6 h, along with 250, 50, 5, 0.5, or 0 µg of free aPD-1/aOX40 or equivalent dose of DINP. After coincubation, nonadherent T-cells were transferred onto an anti-IFN-γ coated ELISpot plate (BD, 551083) and incubated for 72 h before read-out, according to manufacturer protocol. Briefly, ELISpot plates were read out on an AID ELISpot reader (min. size 15, min. gradient > 1), reporting both absolute count and well activity. Well activity is an AID manufacturer-defined measurement of total cytokine release, dependent upon both absolute count and spot signal intensity. Activity values were normalized to the untreated control group.
Mi Y., Smith C.C., Yang F., Qi Y., Roche K.C., Serody J.S., Vincent B.G, & Wang A.Z. (2018). A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy. Advanced materials (Deerfield Beach, Fla.), 30(25), e1706098.
+ Open protocol
+ Expand
3

Evaluating MeVac-encoded FmIL-12 Potency

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 11

Vero-αHis cells were seeded in 15 cm cell culture dishes and infected with MeVac encoding FmIL-12 or eGFP. Supernatants were collected (15 ml per plate) when syncytia had spread over the whole cell layer (ca. 36 h post infection). FmIL-12 concentration was assessed using Mouse IL-12 p70 Quantikine ELISA Kit (R&D Systems). 2×106 freshly isolated splenocytes from a C57BL/6J mouse were resuspended in RPMI 1640 supplemented with 10% FCS, 1% Penicillin-Streptomycin solution and 50 U/ml recombinant murine IL-2 (Miltenyi, Bergisch Gladbach, Germany) with varying concentrations of MeVac encoded FmIL-12 or respective parts of supernatant from cells infected with eGFP encoding MeVac. Splenocytes were seeded in 12-well plates and incubated 48 h at 37° C. 5% CO2. Supernatants were collected and IFN-γ concentration assessed using mouse IFN gamma ELISA Ready-SET-Go!® (eBioscience) according to the instructions of the manufacturer.

US10344067B2. RNA viruses expressing IL-12 for immunovirotherapy (2019-07-09). DEUTSCHES KREBSFORSCHUNGSZENTRUM [DE], RUPRECHT-KARLS UNIVERSITAET [DE]. Inventors: Guy Ungerechts [DE], Christine Engeland [DE], Ruta Veinalde [DE].
+ Open protocol
+ Expand
4

Antigen-Specific CD8+ T-cell Activation and Expansion

Check if the same lab product or an alternative is used in the 5 most similar protocols
OT1 CD8+ T-cells were activated and expanded using the H-2Kb-restricted OVA MHC class I epitope (OVA257–264; SIINFEKL), according to previously published methods.[19 (link)] Antigen-experienced T-cells were viably frozen and subsequently thawed for experiments, allowing cells to recover overnight. Cells were incubated for 6 d with 100 IU mL−1 recombinant murine IL-2, anti-CD3/28 stimulation beads according to manufacturer protocol (Miltenyi, 130-095-925), and 1 µg mL−1 recombinant murine PD-L1 protein (R&D systems, 1019-B7), with media and reagents changed out every 48 h. On day 7, T-cells were coincubated with B16-OVA tumor cells at a 0.25:1 effector to target ratio in 100 µL media for 48 h, along with 250, 50, 5, 0.5, or 0 µg of free aPD-1/aOX40 or equivalent dose of DINP. After coincubation, nonadherent cells were washed thrice from the plate, and remaining cell viability was measured with a CellTiter-Glo Luminescence kit (Promega, G7570), according to manufacturer protocol.
Mi Y., Smith C.C., Yang F., Qi Y., Roche K.C., Serody J.S., Vincent B.G, & Wang A.Z. (2018). A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy. Advanced materials (Deerfield Beach, Fla.), 30(25), e1706098.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!